AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 151 min read$OBIO

Orchestra BioMed Receives $6.1 Million Milestone Payment From Vivasure Acquisition By Haemonetics

Orchestra BioMed (OBIO) received a $6.1M milestone payment from Haemonetics (HAE) following HAE's acquisition of Vivasure. This adds to a prior $5M upfront payment, with potential for $10M more in earnouts. The funds will support OBIO's AVIM and Virtue SAB clinical trials. HAE's stock closed at $106.31, up 3.53%.

Original reporting
rttnews.com
Published Sep 15, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$OBIO
Bullish
medium confidence
Mentioned
$OBIO · $HAE
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$OBIOBullishLow
01

Why it matters

The milestone payment provides additional capital for OBIO's pipeline programs.

02

Market read

Cash proceeds may support OBIO's ongoing trials and could be priced in by investors.

03

What to watch

Future earnouts could increase total proceeds if milestones are met.

Relevance 6/10Novelty 6/10Timing: payment received Sep 14, 2026

Background

Orchestra BioMed holds a strategic stake in Vivasure, which Haemonetics acquired.

Company-level read

Ticker impact

$OBIOBullishMedium confidence
Context

Orchestra BioMed received a $6.1M milestone payment from Haemonetics' acquisition of Vivasure.

Expected impact

Potential modest upside as runway extension is priced in.

Evidence & confidence

The payment is a primary disclosure but the amount is modest for a micro‑cap biotech.

Market effects

Sector

May slightly improve sentiment for small‑cap biotech cash‑flow news.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

The payment is too small to move the stock materially.

Key entities

  • Company
    Orchestra BioMed Holdings, Inc.

    Biotech firm receiving the milestone payment.

  • Company
    Haemonetics Corporation

    Acquirer of Vivasure, payer of the milestone.

Read at source← All news

Related articles

OCT 19
$HAEMedAI 8/10

Haemonetics says FDA clears vascular closure device

Haemonetics announced FDA approval for its PerQseal Elite device, which seals arterial openings in heart and vascular procedures. The company acquired the technology via its 2026 purchase of Vivasure Medical. Shares rose 1.2% in extended trading. Additional clinical data will be presented at an upcoming conference.

finance.yahoo.com1 min
OCT 19
$HAEHighAI 8/10

Haemonetics receives FDA approval for vascular closure device

Haemonetics (HAE) received FDA approval for its PerQseal Elite vascular closure system, expanding its portfolio for large-bore procedures. The device showed 0% major complications in a study, with hemostasis in under a minute. The approval follows the acquisition of Vivasure Medical. HAE plans to present clinical data at an upcoming conference.

investing.com2 min
OCT 19
$HAEMedAI 9/10

Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

Haemonetics (HAE) received FDA approval for its PerQseal® Elite vascular closure system, expanding its large-bore closure device portfolio. The system, acquired via Vivasure Medical, offers sutureless closure for arterial procedures, with clinical data showing rapid hemostasis and no major complications. The company plans to present data at the TCT Conference.

prnewswire.com2 min